Previous 10 | Next 10 |
Interim data from two studies, HBV001 and HBV002, showed that in chronic Hepatitis B (CHB) patients the heterologous prime-boost vector combination, ChAdOx1-HBV + MVA-HBV (VTP-300), induced robust T cells against targeted hepatitis B viral antigens. ChAdOx-1-HBV alone (HBV001) w...
OXFORD, United Kingdom, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter, ended September 30, 2021, and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biophar...
OXFORD, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chief Executive Officer, will be presentin...
The Phase 1 clinical trial was conducted by The King Abdullah International Medical Research Centre (KAIMRC), in the Kingdom of Saudi Arabia (KSA), in partnership with the University of Oxford. Vaccitech retains commercial rights to this vaccine. The ChAdOx1 MERS vaccine candida...
OXFORD, U.K., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced two poster presentations at AASLD’s Liver Meeting® 2021 ...
OXFORD, United Kingdom, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Tom Evans, M.D., Vaccitech’s Chief Scientific Off...
Today, we post our first analysis around Arbutus Biopharma. This small cap developmental concern is focusing on treating hepatitis B. The company is in the process of conducting several mid-stage trials with three different collaboration partners around its main drug candidate, AB-729...
OXFORD, United Kingdom, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today ann...
OXFORD, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmace...
OXFORD, United Kingdom, July 08, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today anno...
News, Short Squeeze, Breakout and More Instantly...
Vaccitech plc Company Name:
VACC Stock Symbol:
NASDAQ Market:
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing nov...
2023-09-27 06:52:40 ET DENVER, Colo., Sept 27, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ: VACC), Siyata Mobile (NASDAQ: SYTA), Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASD...
2023-09-26 07:38:47 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ:VACC), Lifezone Metals (NYSE:LZM), Globus Maritime Ltd. (NASDAQ:GLBS), Siyata Mobile (NASDAQ:SYTA), ESS Tech (NYSE...